Key terms
About DMTK
DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DMTK news
Mar 11
6:30am ET
BTIG Remains a Buy on DermTech (DMTK)
Mar 07
7:15am ET
DermTech price target lowered to $2 from $4 at BTIG
Mar 05
7:14am ET
DermTech price target lowered to $1.50 from $2.50 at Stephens
Mar 01
9:10am ET
DermTech price target lowered to $3.50 from $4.50 at Lake Street
Mar 01
8:55am ET
DermTech (DMTK) Receives a Buy from Lake Street
Feb 29
4:03pm ET
DermTech reports Q4 EPS (56c), consensus (56c)
Feb 26
9:07am ET
Craig-Hallum Releases a Buy Rating on DermTech (DMTK)
Feb 01
8:50am ET
Analysts’ Top Healthcare Picks: EDAP TMS (EDAP), DermTech (DMTK)
Jan 31
4:32pm ET
DermTech announces restructuring, will lay off roughly 15% of workforce
Jan 18
8:21am ET
DermTech study shows DMT’s effectiveness as rule-out test for all skin types
Jan 09
9:09am ET
Craig-Hallum Remains a Buy on DermTech (DMTK)
Jan 07
5:28am ET
DermTech (DMTK) Gets a Buy from BTIG
Jan 02
9:11am ET
BTIG Sticks to Its Buy Rating for DermTech (DMTK)
Dec 31
5:13am ET
BTIG Keeps Their Buy Rating on DermTech (DMTK)
Dec 12
7:33am ET
Alimera Sciences appoints Todd Wood, president, U.S. operations
No recent press releases are available for DMTK
DMTK Financials
Key terms
Ad Feedback
DMTK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DMTK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
